Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase III IZABRIGHT-Lung01 registrational study.
An investigational EGFR x HER3 antibody-drug conjugate showed promising results in a phase III trial for lung cancer patients. The therapy demonstrated a tolerable safety profile and increased clinical activity at the recommended dose of 2.5 mg/kg. The trial found a 33.3% objective response rate, 29.6% confirmed response rate, and a median progression-free survival of 6.9 months. These results support the advancement of the therapy into global Phase III evaluation.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
